Key Takeaways Bristol Myers expands Opdivo into new cHL settings, broadening reach across treatment lines.Label expansions and pipeline progress aim to offset generic pressure on legacy drugs like Revlimid.Oncology competition intensifies as Merck and Pfizer advance bispecifics and diversified cancer pipelines.Bristol Myers Squibb (BMY) recently won FDA and European Commission (EC) approvals for the label expansion of its blockbuster immuno-oncology (IO) drug Opdivo.The FDA approved Opdivo in combination wi ...

Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of Terns | Investor's Business Daily IPO TRENDS: SpaceX Is Just One Unicorn To Watch Merck (MRK) made plans Wednesday to beef up its cancer treatment portfolio with the $6.7 billion acquisition of Terns Pharmaceuticals (TERN). But the takeover could be at risk. The price tag is low considering the startlingly good data Terns put out for its chronic myeloid leukemia treatment, TERN-701, William Blair analyst Andy Hsieh said. The deal values ...

The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.The Financial Times was the first to report the deal.Pipeline Pressure Mounts Ahead Of Keytruda ExpiryThe deal reflects Merck's broader strategy to replenish its pipeline ahead of Keytruda's expected patent expiry as early as 2028.Keytruda, a cancer immunotherapy, generates about $30 billion annually, making it central to the company's growth trajectory.Merck has been among the most aggressive acquirers in bio ...

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on its cancer drug Keytruda expires in two years. Merck received accelerated approval for Keytruda from the Food and Drug Administration in September 2014 to treat advanced or unresectable melanoma. The drug has since been approved to treat more than 15 types of cancers and has been a key contributor to Merck's revenu ...

Merck & Co (NYSE:MRK) M&A announcement March 25, 2026 08:00 AM ET Company ParticipantsCaroline Litchfield - CFODean Li - President of Merck Research LaboratoriesEvan Seigerman - Managing Director and Head of Healthcare ResearchJannie Oosthuizen - EVP and President of Oncology and MSD InternationalJason Gerberry - Managing Director of Equity ResearchLuisa Hector - Head of Global Pharma Equity Research and Co-Head of the Global Pharmaceuticals TeamMarjorie Green - SVP and Head of Oncology, Global Clinical Dev ...

This is CNBC's Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.Happy Wednesday. I spent yesterday evening at a market technicals event and then went to watch the "Hannah Montana 20th Anniversary Special." You might call it the best of both worlds.Stock futures are up this morning after a losing day.Here are five key things investors need to know to start the trading day:1. Peace planU.S. President Donald Trump speaks as he attends Markwayne Mullin's swearing-in as Departme ...

Pharma giant Merck is buying U.S. biotech firm Terns Pharmaceuticals for $6.7 billion, the company said Wednesday.This is the third multibillion-dollar acquisition for Merck over the past year as the company looks to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028. Terns shares rose 5.3% while Merck stock was largely flat in premarket trading. This is breaking news. Please refresh for updates. ...

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv March 25 (Reuters) - Merck (MRK.N), opens new tabsaid on Wednesday it would buy biotech Terns Pharma (TERN.O), opens new tabin a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss for its blockbuster therapy Keytruda. Sign up here. Reporting by ...

The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection. ...

Key Takeaways IBRX is expanding Anktiva beyond NMIBC into broader oncology indications to drive growth.Studies include bladder cancer, NSCLC, pancreatic and other tumors using combo therapies.Strong competition from Merck, Bristol Myers and Roche may challenge market penetration.ImmunityBio’s (IBRX) growth narrative is increasingly tied to the expansion potential of its sole marketed drug, Anktiva, beyond its initial approval in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). While the current ...